CHRS
Coherus Oncology, Inc. · Healthcare · Market cap $219.4M
Coherus Oncology, Inc. (CHRS) has 11 SEC Form 4 filings (11 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jun 10, 2026.
- Industry:Biotechnology
- CEO:Dennis Lanfear
- Employees:144
- HQ:Redwood City, CA, US
- IPO:2014-11-06
No open-market insider trades for CHRS (Coherus Oncology, Inc.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Frequently asked questions
How many SEC Form 4 insider filings does CHRS have?
Coherus Oncology, Inc. (CHRS) has 11 SEC Form 4 filings (11 transaction rows) in the rolling 365-day window, disclosed by 0 distinct insiders. Most recent filing: Jun 10, 2026.
When was the most recent SEC Form 4 filing for CHRS?
The most recent Form 4 filing for CHRS on Tracefour is dated Jun 10, 2026.
Can I get alerts for CHRS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Coherus Oncology, Inc. (CHRS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Coherus Oncology, Inc. is in the Healthcare sector.